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To describe the long term outcomes, treatment pathways and risk factors for patients 
diagnosed with Hypoplastic Left Heart Syndrome (HLHS) in England and Wales. 
Methods 
The UKs national audit database captures every procedure undertaken for congenital heart 
disease and updated life status for patients resident in England and Wales. HLHS patients 
born between 2000 and 2015 were identified using codes from the International Paediatric 
and Congenital Cardiac Code. 
Results 
There were 976 patients with HLHS. Of these, 9.6% had a pre-pathway intervention, 89.5% 
underwent a traditional pathway of staged palliation and 6.4% of infants underwent a hybrid 
pathway. Patients undergoing pre-pathway procedures or the hybrid pathway were more 
complex, exhibiting higher rates of prematurity and acquired comorbidity. Pre-pathway 
intervention was associated with the highest in-hospital mortality (34.0%). 
44.6% of patients had an off pathway procedure after their primary procedure, most 
frequently stenting or dilation of residual or re-coarctation and most commonly occurring 
between Stage 1 and 2. 
The survival rate at 1 year and 5 years was 60.7% (95% CI 57.5-63.7) and 56.3% (53.0-
59.5) respectively. Patients with an antenatal diagnosis (multivariable hazard ratio (MHR) 
1.63 (95% CI 1.12-2.38)), low weight (<2.5kg) (MHR 1.49 (1.05-2.11)) or the presence of an 
acquired comorbidity (MHR 2.04 (1.30-3.19)) were less likely to survive. 
Conclusion 
Treatment pathways amongst HLHS patients are complex and variable. It is essential that 
the long term outcomes of conditions like HLHS that require serial interventions are studied 





What is already known about this subject? 
 Hypoplastic left heart syndrome (HLHS) represents one of the most complex and 
high risk forms of congenital heart disease. 
 Treatment options have evolved dramatically in the last thirty years. 
 Data reporting longer term outcomes reflecting current practice are scarce. 
What does this study add? 
 We have undertaken the first analysis of UK national audit data on procedures to 
report longer-term patient based outcomes for HLHS. 
 Interventional treatment pathways followed for HLHS are complex and highly 
variable. 
 56.3% of patients survived to age five years and nearly half of patient had an 
additional unplanned intervention. 
How might this impact on clinical practice? 
 The information presented on longer-term outcomes may in future be used to inform 
families during decision making for their child. 
 It is essential that the long term outcomes of conditions like HLHS that require serial 
interventions are used for audit to provide a fuller picture and to inform quality 






Hypoplastic left heart syndrome (HLHS) represents one of the most complex and high risk 
forms of congenital heart disease (CHD), and treatment options have evolved dramatically in 
the last thirty years1. 
The possible treatment pathways that patients with HLHS can undergo in the UK are 
summarised in Figure 1. Treatment generally begins soon after birth, and completion of the 
Stage 3 Fontan operation usually takes place before primary school age. A recently 
introduced alternative to the traditional surgical pathway is the combined surgical and 
interventional cardiology pathway referred to as the hybrid procedure2. A minority for whom 
these pathways fail are diverted to transplantation. 
Numerous reports document the early surgical outcomes following the Stage 1 operation for 
HLHS3,4, recognised as amongst the most technically challenging in paediatric cardiac 
surgery5. Interstage deaths between discharge following Stage 1 or hybrid procedure and 
the Stage 2 procedure have been a focus of quality assurance efforts6,7.  
Studies capturing staged interventions and longer term HLHS outcomes that go beyond 
single centre experience are rare but include the prospective multi-centre Single Ventricle 
Reconstruction (SVR) trial which reported in 2016 that of 549 neonates enrolled in the first 
stage of the trial, 327 (60%) transplant free survivors between the ages 2 and 4 years 
subsequently underwent a Fontan-type procedure8. A propensity score matching paired 
study of 338 patients over 21 institutions in North America reported survival at 6 years after 
Norwood Stage 1 of 70% and 55% for patients undergoing right-ventricle-to-pulmonary-
artery conduit and Modified Blalock-Taussig shunt respectively, with 52% having transitioned 
to Stage 39. A registry study of patients with a Fontan-type circulation from Australia and 
New Zealand published in 2014, that contained only 88/1006 with a HLHS diagnosis10, 
suggested HLHS had the poorest outcome.  A systematic review of long-term outcomes for 
CHD contained minimal information specific to HLHS in the current era11 
Given the paucity of long term data for patients with HLHS at population level, we explored 
this within the mandatory procedure based registry for the UK, the National Congenital Heart 
Disease Audit (NCHDA), operational since 2000 and part of the UK National Institute of 
Cardiovascular Outcomes Research (NICOR)12, in which all HLHS patients who have 
undergone a procedure are represented. In a previous research letter, we published a 
summary of outcomes for HLHS based on this NCHDA data13. We now aim to describe the 
case mix and interventional pathways in more detail and to evaluate risk factors for longer-
term survival in HLHS.  
METHODS 
Approvals 
The study was approved by the NCHDA Research Committee and the National Health 
Service (NHS) Healthcare Quality Improvement Partnership (Study number 14CONG03). 
Further ethics committee approval and patient consent were waived.   




The source data for the study consisted of all records of interventional catheter and cardiac 
surgical procedures in the NCHDA relating to English and Welsh patients between 1 April 
2000 and 31 March 2015. Data submission to the NCHDA is mandatory and subject to 
external data validation. Each procedure record in the NCHDA contains several diagnostic 
and procedure codes based on the International Paediatric and Congenital Cardiac Code 
(IPCCC)14, and further demographic and procedure information. NCHDA procedure data 
quality is excellent as this has historically been the focus. Data quality for non-procedural 
information has improved and has been high since 200615, partly due to greater scrutiny, 
with centre specific outcomes published online from 2007.  
 Case ascertainment, inclusion and exclusion criteria 
Patients with HLHS, defined as those with a small left ventricle, left sided valvar stenosis or 
atresia, normally related great arteries and no common atrioventricular junction16 were 
identified based on IPCCC codes appearing in their records in the NCHDA and their survival 
ascertained according to the processes detailed in Appendix 1. Since patients that do not 
receive any surgical or interventional cardiology procedures are not captured in the NCHDA, 
these patients do not feature in the analyses. 
Classification and timing of procedures 
The allowed timings for the components of HLHS treatment pathway were a primary 
procedure (Stage 1 Norwood or hybrid) within three months of birth, a Stage 2 or 
comprehensive Stage 2 by 1.5 years of age and a Stage 3 by 8.5 years of age. These age 
limits were deliberately broad to include patients with unusual procedural histories.  
In addition to identifying procedures inconsistent with HLHS within the case ascertainment 
process outlined in Appendix 1, procedures were classified as:  
Pre-pathway procedures such as stabilisation procedures for neonatal HLHS including 
bilateral pulmonary artery banding17 and enlargement of a restrictive atrial septum18 or the 
aortic valve or arch in neonates with hypoplastic left ventricle where subsequent events 
indicate biventricular strategy was unsuccessful19. 
Off pathway procedures that may be required in patients with HLHS, including surgeries and 
interventional catheterisations20.  
Ambiguous procedures for which there was insufficient information.  
The NCHDA does not consistently collect all diagnostic catheters, mechanical support 
procedures and non-cardiovascular operations so such procedure types were not 
considered in the analyses.  
Demographic data and risk factors 
Other data available included: gender, ethnicity (NCHDA contains the categories White, 
Black, Asian, Other or Unknown), socioeconomic status (Index of Multiple Deprivations 
(IMD) 201021) for English patients, antenatal diagnosis (yes, no, unknown), comorbidities22, 
and prematurity (birth at gestation less than 37 weeks).  
The following additional factors were derived from records corresponding to pre-pathway 




procedural mechanical ventilation, shock or severe acidosis22) and low weight (less than 
2.5kg3). 
Descriptive analysis 
From each patient history, a graphical timeline was constructed of the procedures 
undergone from birth to death or censoring. An array of these timelines was then produced 
for patients on a traditional and hybrid pathway separately, with timelines arranged from top 
to bottom in decreasing order of time to death or censoring.  
Statistical Methods 
Given that the data quality in NCHDA is recognised to be poor for non-procedural factors 
prior to 2006, which coincides with when the hybrid pathway was introduced in the UK2,23, 
patients treated before 2006 were analysed as a separate subgroup (“the early era”). For 
patients treated between 2006 and 2015 (“the recent era”), those following a traditional 
pathway were analysed separately from those following a hybrid pathway.  Variables for 
which data quality was poor are not presented for the early era. 
Unadjusted bivariate comparisons of demographics in the recent era between patients 
embarking on the traditional pathway and on a hybrid pathway were performed using 
Fisher’s exact test.  
The median and interquartile ranges of age at procedure and length of stay in hospital at 
different stages of treatment were calculated. Competing risks analysis was used to explore 
differences in the timing of operations and in interstage mortality between eras and between 
traditional and hybrid pathways.  
The frequency and type of off pathway procedures were determined and compared using 
Poisson regression.  
Survival analysis was carried out using the Kaplan-Meier approach, with death representing 
failure. As the primary study objective was to ascertain long-term condition based outcomes, 
we do not treat heart transplantation as an end point in our survival analysis. 
Univariable and multivariable cox proportional hazard regression was carried out on 
demographic and other patient factors for the recent era patients from England. Welsh 
patients were excluded as deprivation data was not available. Patients were considered “at-
risk” from the time of their initial procedure until death or censoring. Patients with missing 
data on the risk factors were excluded. We carried out sensitivity analysis comparing the 
univariable cox model results for two extreme cases of all patients with missing data for a 
particular risk factor being allocated as having or not having the risk factor in question.   
Data were analysed using the Stata statistical software package. (Stata Statistical Software: 
Release 13. College Station, StataCorp LP, Texas, USA). 
RESULTS 
The dataset  
The exclusions that were made from the dataset are summarised in Figure 2, and resulted in 




Demographics and time eras  
There were 296 patients commencing treatment in the early era, including 14 patients 
undergoing pre-pathway interventions, 8 of whom survived to Stage 1.  
In the recent era, 584 patients started a traditional pathway and 62 patients a hybrid 
pathway. A total of 80 recent era patients underwent pre-pathway interventions, 46 of whom 
continued to primary procedure (45 embarking on the traditional pathway and 1 embarking 
on the hybrid pathway). The 34 patients that did not reach their primary procedure are 
included with the dominant traditional pathway cohort for analysis purposes. 




Table 1: Characteristics of patients with HLHS commencing interventions in the early era and for patients commencing the 
traditional and hybrid pathway in the recent era 





Ethnicity    
White 195 (65.9%) 450 (72.8%) 43 (69.4%) 
Black 13 (4.4%) 36 (5.8%) 2 (3.2%) 
Asian 23 (7.7%) 84 (13.6%) 13 (21.0%) 
Other 9 (3.0%) 25 (4.0%) 3 (4.8%) 
Unknown 56 (18.9%) 23 (3.7%) 1 (1.6%) 
Gender    
Male 186 (62.8%) 385 (62.3%) 32 (51.6%) 
Female 102 (34.5%) 231 (37.3%) 30 (48.4%) 
Unknown 8 (2.7%) 2 (0.3%) 0 (0.0%) 
IMD Quintile    
Most deprived 86 (29.1%) 212 (34.3%) 28 (45.2%) 
2nd most deprived 61 (20.6%) 140 (22.7%) 11 (17.7%) 
Mid deprived 49 (16.6%) 72 (11.7%) 11 (17.7%) 
2nd least deprived 43 (14.5%) 84 (13.6%) 7 (11.3%) 
Least deprived 33 (11.1%) 59 (9.5%) 3 (4.8%) 
Unknown 24 (8.1%) 51 (8.3%) 2 (3.2%) 
Antenatal Diagnosis    
No  113 (18.3%) 10 (16.1%) 
Yes  501 (81.1%) 51 (82.3%) 
Unknown  4 (0.6%) 1 (1.6%) 
Congenital 
Comorbidity 
   
No  555 (89.8%) 47 (75.8%) 
Yes  63 (10.2%)† 15 (24.2%)† 
Premature    
No  601 (97.2%) 56 (90.3%) 
Yes  17 (2.8%)† 6 (9.7%)† 
Low weight*    
No 247 (83.4%) 542 (87.8%) 35 (56.5%) 
Yes 45 (15.2%) 76 (12.3%)† 27 (43.5%)† 
Unknown 4 (1.4%) 0 (0.0%) 0 (0.0%) 
Acquired 
Comorbidity* 
   
No  588 (95.1%) 49 (79.0%) 
Yes  30 (4.9%)† 13 (21.0%)† 
Increased Severity of 
Illness* 
   
No  505 (81.7%) 49 (79.0%) 
Yes  113 (18.3%) 13 (21.0%) 
Total 296 618 62 
*Risk factor applies at or prior to primary procedure 
†A statistically significant higher proportion of hybrid patients have congenital comorbidities (p=0.002), 
are premature (p=0.013), and have a low weight (p<0.001) or an acquired comorbidity (p<0.001) at 
primary procedure. 
 
The patients following a hybrid pathway were more complex than those following a 
traditional pathway, with a higher incidence of patients with congenital comorbidities, 




Interventional treatment pathways 
Figure 3 shows the array of timelines of treatment for traditional and hybrid pathway patients. 
One notable feature is the variability in the ages at which Stage 3 procedures were 
undertaken.  
Table 2 gives the frequencies of pre-pathway and pathway procedures, summaries of the 
age and weight at which the procedure occurred; the hospital length of stay, in-hospital 
mortality and interstage mortality. The highest in-hospital mortality rates followed the pre-
pathway procedures for both eras, followed by the mortality rates linked to Stage 1 surgery 
in the early era and then hybrid procedures in the recent era. Statistically significant 
differences between eras are highlighted in Table 2.  
Pre-pathway procedures 
Pre-pathway procedures, which had the highest mortality were undertaken in 94 more 
complex patients who had a higher incidence of acquired comorbidity (p=0.021), severity of 
illness indicator (p<0.001) and prematurity (p=0.043) in the recent era. Components of pre-
pathway procedures included: 58 to create or enlarge the interatrial communication (surgery 
or catheter), 40 to place bilateral pulmonary arterial bands, 4 surgeries to relieve obstructed 
pulmonary veins and 15 other, miscellaneous or incompletely coded procedures. There were 
also 21 operations to relieve obstruction to the aortic arch, 15 trans-catheter balloon dilations 
of the aortic valve, and 4 neo-aortic valvoplasty procedures representing neonates where an 









Median age (IQR) 






 (%) (95% CI) 
Interstage 
mortality  








Traditional pathway 296 (30.3)      
Pre-pathway 14 (4.7) 2 (2-4) days 7 (2-17) days 3.1 (2.0-3.5)  35.7 (12.8-64.9)   
Stage 1 290 (98.0) 4 (3-7) days 16 (10-26) days 3.1 (2.7-3.4)  30.0 (24.8-35.9)†  13.6 (9.3-18.8) 
Stage 2 169 (57.1) 5.7 (4.7-7.7) months† 8 (6-14) days 6.4 (5.6-7.0)   1.8 (0.4-5.1)  6.8 (3.6-11.4) 
Stage 3  141 (47.6) 52.0 (41.4-64.2) months 14 (9-22) days 15.5 (14.0-16.8)  2.1 (0.4-6.1)   










Traditional pathway 618 (63.3)      
Pre-pathway 79 (12.8) 3 (1-7) days 9 (2-21) days 3.0 (2.6-3.4)  34.2 (23.9-45.7)   
Stage 1 584 (94.5) 4 (3-6) days 20 (11-33) days 3.1 (2.8-3.5)  19.0 (15.9-22.4)†  11.3 (8.6-14.4) 
Stage 2 394 (63.8) 5.1 (4.0-6.3) months† 8 (6-16) days 6.1 (5.3-6.9)  4.1 (2.3-6.5)  7.8 (5.0-11.2) 
Stage 3 182 (29.4) 48.5 (39.5-55.6) months 16 (11-23) days 15.2 (13.7-16.7)  0.5 (0.0-3.0)   
Heart Transplant 8 (1.3) 35.4 (3.4-61.0) months 55 (32-71) days 13.5 (5.1-15.6)  12.5 (0.3-52.7)   
Hybrid pathway  62 (6.4)      
Pre-pathway 1 (1.6) 0 (0-0) days 6 (6-6) days 3.7 (3.7-3.7)  *  
Hybrid 62 (100.0) 5 (3-7) days 18 (7-30) days 2.7 (2.3-3.2)  25.8 (15.5-38.5)   
Stage 1 18 (29.0) 77 (66-99) days 19 (10-62) days 3.1 (2.8-4.1)  11.1 (1.4-34.7)  28.6 (15.9-42.6)‡ 
Stage 2 13 (21.0) 7.1 (5.9-8.5) months 18 (7-37) days 5.7 (4.7-6.5)  0.0 (0.0-24.7)   
Comprehensive stage 2 14 (22.6) 3.9 (3.7-5.2) months 15 (9-37) days 4.8 (4.2-5.7)  14.3 (1.8-42.8)  4.0 (0.0-17.0)§ 
Stage 3 9 (14.5) 42.1 (33.9-45.5) months 14 (11-19) days 13.5 (11.9-15.0)  0.0 (0.0-33.6)   
Heart transplant 1 (1.6) 3.1 (3.1-3.1) months 148 (148-148) days 3.6 (3.6-3.6) 0.0 (0.0-97.5)   
*The inclusion criteria for the Hybrid pathway was a patient undergoing a Hybrid procedure, so the survival following any pre-pathway procedures was necessarily 100% for 
this group of patients. 
†There was a statistically significant reduction between the early and recent era for traditional pathway patients in terms of younger age at Stage 2 surgery (p<0.001) and in 
hospital mortality for Stage 1 surgery (p<0.001) 
‡This includes all mortality following discharge from the Hybrid approach procedure until completion of Stage 2. 





Off Pathway procedures 
The frequencies of each off-pathway procedure type are included in Appendix 2, the most 
common being revision of the arterial shunt or right ventricle to pulmonary artery valveless 
conduit (Sano) and stenting or dilation of residual or re-coarctation. 44.6% had a subsequent 
off pathway procedure following their primary procedure; rates are shown in Table 3. The 
rate of off pathway interventions increased between the early and recent eras (p<0.001), 
driven by interventions undertaken between Stages 1 and 2, most notably interventional 
catheterisations in the hybrid cohort.  
Table 3: The rate of off pathway procedures occurring at different stages of the treatment pathway for HLHS by era 
 Rate (per 100 patient-year) 
 
All Early era 
Recent era -  
Traditional 
pathway 
Recent era -  
Hybrid pathway 



















































































Figure 4 shows Kaplan-Meier survival curves by era and by pathway for the recent era, 
inclusive of pre-pathway deaths in the traditional cohort. The 1 and 5 year survival in the 
early era were 56.6% (95% CI 50.7-62.1%) and 53.8% (47.9-59.3%).  For the recent era, the 
1 and 5 year survival rates were 63.9% (59.9-67.6%) and 58.1% (53.8%-62.2%) for the 
traditional patients versus 47.2% (33.9-59.4%) and 47.2% (33.9-49.4%) for the hybrid 
patients. A cox proportional hazards model, presented in Table 4, showed that patients with 
antenatal diagnosis, a low weight or acquired comorbidity prior to primary intervention were 
all less likely to survive.  For traditional pathway patients in the recent era, whether the Stage 





Table 4: Univariable and multivariable hazard ratios for recent era patients (n=599) 
Patient Factor 
Univariable hazard ratio 
(95% CI) 
Multivariable hazard 
ratio (95% CI)  
White  
(Ref: Non-white) 
0.80 (0.61-1.06) 0.73 (0.54-0.98) 
Male  
(Ref: Female) 
0.95 (0.74-1.22) 1.04 (0.79-1.36) 
Deprivation Quintile 
(Ref: Most deprived) 
  
2nd Most deprived 1.44 (1.05-1.99) 1.63 (1.15-2.29)* 
Mid deprived 1.07 (0.71-1.61) 1.19 (0.78-1.82) 
2nd least deprived 1.30 (0.89-1.89) 1.54 (1.02-2.33)* 
Least deprived 1.29 (0.84-1.99) 1.47 (0.91-2.37) 
Antenatal Diagnosis  
(Ref: No antenatal diagnosis) 
1.45 (1.02-2.0.6) 1.63 (1.12-2.38)* 
Congenital Comorbidity  
(Ref: No congenital 
comorbidity) 
1.34 (0.94-1.91) 1.31 (0.90-1.91) 
Prematurity  
(Ref: Full term) 
1.20 (0.64-2.27) 1.01 (0.51-1.99) 
Low weight  
(Ref: >2.5kg at primary 
procedure) 
1.48 (1.0.9-2.02) 1.49 (1.05-2.11)* 
Acquired Comorbidity  
(Ref: No acquired comorbidity) 
1.97 (1.29-3.00) 2.04 (1.30-3.19)* 
Increased Severity of illness 
(Ref: No severity of illness 
indicator) 
0.87 (0.63-1.22) 0.86 (0.61-1.22) 
*Patients in the 2nd most (p=0.005) and 2nd least (p=0.042) deprived IMD quintile, with an antenatal diagnosis 
(p=0.011), or a low weight (p=0.024) or an acquired comorbidity (p=0.002) at primary procedure had a 
statistically significant increased hazard ratio compared to the reference group. 
Sensitivity Analysis 
If all patients with missing ethnicity data were assumed to be non-white, non-white patients 
had a significantly increased hazard ratio (p=0.021) compared to white patients, and if all 
patients missing data on antenatal diagnosis were assumed to have not had an antenatal 
diagnosis, antenatal diagnosis ceased to significantly increase the hazard ratio (p=0.124). 
Other comparisons of patients with missing data for ethnicity, sex and antenatal diagnosis 
did not change the univariable results shown in Table 2. 
 
DISCUSSION 
This longitudinal analysis on procedure based registry data offers a unique insight into the 
journey faced by patients with a complex disease like HLHS in terms of interventions and 




infancy and childhood. The variations to the standard treatment pathway for HLHS, and the 
outcomes, are made available to inform counselling of families, particularly considering that 
the vast majority of cases are currently prenatally diagnosed. This provides a more valid 
perspective than reliance on data from procedure based datasets.  
The variation in treatment is shown by the 9.6% of patients that had a pre-pathway 
procedure. Such pre-pathway interventions are required for the highest risk neonates17 and 
over a third did not survive to a primary procedure. The use of the hybrid procedure was 
infrequent at 6.4% (in 2015, North American Centres represented within the Society of 
Thoracic Surgeons Congenital Heart Surgery Database reported that 13% of primary 
procedures for HLHS were hybrids24) and reserved for the smallest and most complex 
patients, who had poorer outcomes.  Amongst patients in the whole cohort only 1.8% 
underwent a transplant, this occurring at various stages in the treatment pathway but 
notably, because of low donor organ availability in the UK, no patient had transplantation as 
their primary intervention, an approach reported from North America25.  
Although in-hospital mortality following the Stage 1 operation improved in the recent era and 
the age at which Stage 2 was undertaken fell (this has previously been reported in UK26 and 
US data7) mortality rates across later stages in the journey were unchanged. As has been 
reported in other cohorts27, there was significant interstage mortality between Stages 1 and 
2. Previous focus on this interstage period has enabled the evaluation of therapeutic 
interventions to reduce mortality, including additional surveillance of patients in home 
monitoring programmes 6. Furthermore, non-randomised studies of digoxin use between 
Stages 1 and 2 indicate this is linked to reduced mortality28. Our study data identified further 
interstage deaths between Stages 2 and 3, a less well explored phase of the patient journey 
for HLHS. This interstage mortality and the variability in age at Stage 3 suggest that these 
phases may be future targets for quality improvement. In this regard we note that the median 
Stage 3 age in the recent era was 4 years compared to 2.8 years reported in the SVR trial8 .  
Previous population based studies of HLHS have predominantly reported outcomes at one 
year of age29, or are focussed on even shorter time periods25 whereas our study includes a 
median follow up time in survivors of 5 years 2 months. Our survival analyses suggested that 
although amongst patients on the traditional pathway there was improved survival in the later 
era, this was accompanied by the evolution of complex cohort of hybrid patients with poorer 
outcomes. One explanation to note for the modest progress in overall survival across the 
HLHS population is the reported trend in the UK towards acceptance of more complex 
candidates for surgery.26 
The high rate of antenatal diagnosis for HLHS in this study (81% in the recent era) indicates 
excellent performance of obstetric sonographers screening for this disease. Although it is 
unsurprising that patients who were smaller and sicker at primary intervention had poorer 
outcome, some readers may be surprised that those with antenatal diagnosis also did worse, 
even after adjustment for size and comorbidities. This supports a previously stated 
hypothesis that antenatally diagnosed patients are more likely to display higher risk disease 
subtypes30, which in HLHS specifically includes worse forms of HLHS anatomy that are not 
consistently collected within NCHDA (for example, tricuspid valve regurgitation). The small 
but significant relationship between non-white ethnicity and poorer outcomes, and the 
complex relationship between deprivation and outcomes requires further work to fully 




How do these outcomes compare to other data?  
The overall in-hospital mortality rates reported for our study cohort (Stage 1, 22.7%, Stage 2, 
3.6% and Stage 3, 1.2%) compare well to other studies3,10,20,31.  Considering survival rates 
for HLHS beyond one year; outcomes of our study cohort cannot be directly compared with 
the results of the Wilder study9 of outcomes for neonates undergoing Stage 1 Norwood from 
21 North American Institutions between 2005 and 2014, because of the large number of 
exclusions in that study. Amongst 692 consecutive neonates meeting the diagnostic criteria 
for inclusion, 454 underwent a traditional pathway but reported outcomes are only available 
for the 339 included in the propensity- matched paired analysis. The SVR trial, included 549 
HLHS patients who underwent a Norwood type operation at 15 North American sites 
between 2005 and 2008 and excluded patients with major congenital or acquired 
abnormalities likely to affect survival3. The SVR trial reported 32.2% of patients were 
deceased at 3 years (and 20 survivors transplanted20). After removal of the patients 
undergoing only pre-pathway intervention, the three year mortality in the recent era cohort of 
traditional pathway patients in our study was very similar at 36.0%, noting that in contrast to 
SVR our cohort did include patients with additional congenital anomalies and moreover was 
population based.  
The increase in the rate of off pathway interventions between the early and recent era in our 
study suggests that the approach to interstage interventions has become more proactive. 
Increased patient complexity, due to improved early survival and an emerging complex 
hybrid population could contribute to this. Nonetheless the rate of off pathway procedures is 
lower than the rate reported in the 3 year follow up of the SVR trial in which 164.3 cardiac 
surgeries and 43.1 catheter interventions per 100 patient years from Norwood to 3 years is 
documented20, although the cohorts and time periods considered are not directly 
comparable.   
Study limitations  
As with any registry based study, the retrospective analysis of an observational dataset 
holds inherent limitations and is limited by data quality. Of particular note, there are two 
variants of the Stage 1 procedure (the classic Norwood where pulmonary blood flow is either 
provided by a Blalock-Taussig shunt or a right ventricle to pulmonary artery valveless 
conduit (Japanese (or Sano) modification)) 3,20,27. Previous studies have shown significant 
differences in outcomes for patients undergoing the two variants3,9. Regrettably within the 
NCHDA the vast majority of Stage 1 surgeries (86.0%) do not include sufficient information 
to determine which of these two types of operation was performed. We took an inclusive 
approach within this registry based study and included all patients where the diagnosis was 
HLHS, irrespective to reasonable variations in the timing of procedures or where unusual 
additional procedures were undertaken; since this represented our best assessment of the 
true picture of events for patients with HLHS. As stated only patients that underwent at least 
one procedure are captured within the source data.  
Summary and future directions 
Based on review of published HLHS outcomes, we note that current outcomes for intervened 
HLHS in England and Wales are well up to international standards. The analyses of ‘longer-




given the range and complexity of possible treatment pathways that a patients follow, and 
the difficulty in determining a pure population.  
Nonetheless, it is essential to take the analyses of outcomes, in particular for higher risk 
conditions, such as HLHS, that require serial interventions, in this direction in order to 
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Figure 1: The possible treatment pathways for patients born with HLHS in the UK 
Figure 2: Exclusions made during the case ascertainment process 
Figure 3. Treatment and outcome timeline for traditional pathway (n=914) and hybrid 
pathway patients (n=62). Each dark blue line represents a patient, with different markers for 
the interventions and events during their treatment. Hybrid; Stage 1; Stages 2 (or 
comprehensive stage 2) and Stage 3 are shown with pink, orange, purple and green 
respectively. Heart transplants undertaken are shown in yellow, and any off pathway 
procedures are shown in blue. A patient’s “known lifespan” line ends either at censoring alive 
or death, with deaths show in red. As there are many traditional pathway patients than hybrid 
pathway patients, each individual patient timeline cannot be discerned for traditional pathway 
patients. 
Figure 4. Kaplan-Meier survival plot and 1 and 5 year actuarial survival displaying 
separately: patients commencing treatment in the early era (n=296), in the recent era on the 
traditional surgical pathway (n=618) and the hybrid pathway (n=62) 
 
